Pulmonary Arterial Hypertension

Current Location

39 Pulmonary Arterial Hypertension Trials Near You

Power is an online platform that helps thousands of Pulmonary Arterial Hypertension patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Ralinepag for Pulmonary Arterial Hypertension

Columbus, Ohio
This trial is testing ralinepag, a medication being developed for the treatment of pulmonary arterial hypertension (PAH). It aims to see if adding ralinepag to their usual treatments can improve their condition. The medication works by relaxing and opening up the blood vessels in the lungs, which can lower the pressure and improve blood flow.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

1000 Participants Needed

Macitentan for Pulmonary Hypertension

Columbus, Ohio
This trial is testing macitentan, a drug that helps lower lung blood pressure, in children with pulmonary arterial hypertension. Macitentan has shown significant effectiveness in improving the condition of patients with pulmonary arterial hypertension.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:1 - 17

165 Participants Needed

Seralutinib for Pulmonary Arterial Hypertension

Columbus, Ohio
This trial is testing a medication called seralutinib to see if it can help people with a specific type of lung disease (PAH) improve their ability to exercise. The medication works by blocking signals that cause the blood vessels in the lungs to tighten and narrow. Seralutinib is delivered via inhalation and is being developed for patients with pulmonary arterial hypertension. The goal is to see if this can reduce lung pressure and delay worsening of the disease.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

350 Participants Needed

Sotatercept for Pulmonary Arterial Hypertension

Columbus, Ohio
This trial is testing sotatercept, a medication for high blood pressure in the lungs, in adults with PAH who have completed earlier studies. It aims to see if the medication is safe and effective over a long period. Sotatercept helps lung blood vessels function better, reducing lung pressure. Sotatercept has shown promising results in earlier studies for reducing lung pressure and improving exercise tolerance in patients with pulmonary arterial hypertension (PAH).
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

815 Participants Needed

Ralinepag for Pulmonary Arterial Hypertension

Columbus, Ohio
This trial tests ralinepag, a medication for lung disease, on patients with PAH who participated in earlier research. It aims to improve blood flow in the lungs by relaxing blood vessels and reducing pressure.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 3

1000 Participants Needed

Treprostinil for Pulmonary Arterial Hypertension

Columbus, Ohio
The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4

52 Participants Needed

GB002 for Pulmonary Arterial Hypertension

Columbus, Ohio
This trial will study the long-term effects of GB002 (seralutinib) in patients who were part of an earlier study for Pulmonary Arterial Hypertension (PAH). Seralutinib is a new treatment developed for PAH and has shown better results compared to another treatment in early studies.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

74 Participants Needed

Aria CV System for Pulmonary Arterial Hypertension

Columbus, Ohio
This trial is testing a new device called the Aria CV PH System, which helps manage high blood pressure in the lungs and supports heart function. It is aimed at patients with pulmonary hypertension and related heart issues. The study will check if the device is safe and effective over a period of several months to a few years.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

30 Participants Needed

Inhaled Vardenafil for Pulmonary Arterial Hypertension

Columbus, Ohio
This trial is testing an inhaled medication called RT234. It aims to help people with pulmonary arterial hypertension (PAH) breathe better and exercise more easily. The medication works by widening the blood vessels in the lungs, making it easier for the heart to pump blood. RT234 is being developed to improve exercise tolerance and symptoms in patients with PAH.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

42 Participants Needed

Sotatercept for Pulmonary Arterial Hypertension

Cincinnati, Ohio
This trial is testing a medication called sotatercept to see if it is safe and how it acts in children with high blood pressure in the lungs, who are already on standard treatments. The study will last for several months. Sotatercept has shown promise in improving exercise tolerance in adults with pulmonary arterial hypertension.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:1 - 17

42 Participants Needed

High-Dose Macitentan for PAH

Cincinnati, Ohio
This trial is testing if a higher dose of macitentan can better help patients with pulmonary arterial hypertension by improving blood flow in their lungs. Macitentan has shown promise in helping patients by slowing down the disease and improving their health.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

935 Participants Needed

Sotatercept for Pulmonary Arterial Hypertension

Cincinnati, Ohio
Researchers are looking for other ways to treat people with PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs. The goal of the study is to learn: * What happens to different doses of sotatercept in a person's body over time when it is given using weight-banded doses compared to weight-based doses. There may be differences in how the medicine works with the new dosing method (weight-banded dosing) being studied in this trial. * About the safety of sotatercept and if people tolerate it
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

160 Participants Needed

Sotatercept for Pulmonary Arterial Hypertension

Cincinnati, Ohio
This trial is testing sotatercept, a new medication, to see if it can help people with a specific type of high blood pressure in the lungs (PAH) when added to their usual treatment. The study focuses on patients who are newly diagnosed and at higher risk of their condition worsening. Sotatercept aims to reduce the pressure in the lung's blood vessels, potentially slowing down disease progression. Sotatercept has shown significant reduction in pulmonary vascular resistance and maintained clinical efficacy in previous studies.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

444 Participants Needed

KER-012 for Pulmonary Arterial Hypertension

Cincinnati, Ohio
This trial is testing KER-012, a new injectable medication, in adults with a specific type of high blood pressure in the lungs. The goal is to see if it can lower lung blood pressure and help patients walk better.

Trial Details

Trial Status:Active Not Recruiting

113 Participants Needed

Sotatercept for Pulmonary Arterial Hypertension

Cincinnati, Ohio
This trial is testing sotatercept added to current treatments for patients with severe PAH who are at high risk of death. The goal is to see if it can lower lung blood pressure and improve patient outcomes. Sotatercept, which modulates bone morphogenic protein receptor type 2 (BMPR2) signaling, showed promising results in earlier studies.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting

172 Participants Needed

Mono vs Dual Therapy for Pediatric Pulmonary Hypertension

Cincinnati, Ohio
The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:3 - 18

100 Participants Needed

Selexipag for Pulmonary Arterial Hypertension

Cincinnati, Ohio
The purpose of this study is to evaluate whether the addition of selexipag to standard of care treatment delays disease progression in children with Pulmonary Arterial Hypertension (PAH) in comparison to placebo.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:2 - 17

138 Participants Needed

Inhaled Treprostinil for Pulmonary Arterial Hypertension

Cincinnati, Ohio
The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

92 Participants Needed

Empagliflozin for Pulmonary Arterial Hypertension

Cleveland, Ohio
Randomized, triple-masked, parallel arm clinical trial of empagliflozin versus placebo in pulmonary arterial hypertension (PAH) participants on stable approved PAH-targeted medical therapy.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

78 Participants Needed

Nutrition and Exercise for Pulmonary Arterial Hypertension

Cleveland, Ohio
The purpose of this study is to investigate the extent to which diet and exercise may improve PAH through the modulation of insulin sensitivity. The central hypothesis is that dysregulated glucose metabolism elicits a response in PAH patients that can be modified by exercise and diet, thereby leading to improvements in pulmonary vascular disease.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

34 Participants Needed

Why Other Patients Applied

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

Seralutinib for Pulmonary Arterial Hypertension

Pittsburgh, Pennsylvania
This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

300 Participants Needed

L606 Inhalation Suspension for Pulmonary Arterial Hypertension

Pittsburgh, Pennsylvania
This trial tests a new medication called L606 in patients with specific types of lung disease. It aims to see if L606 is safe, helps patients breathe better, and improves their quality of life compared to an existing treatment called Tyvaso. LIQ861 is a novel dry-powder formulation of treprostinil, similar to the inhaled, nebulized treprostinil (Tyvaso®).
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

28 Participants Needed

PET Imaging for Pulmonary Arterial Hypertension

Pittsburgh, Pennsylvania
This trial uses a special PET scan with a tracer called 18F-FGln to study how a substance called glutamine is taken up in the lungs and heart of patients with different types of pulmonary arterial hypertension (PAH). The goal is to see if this method can help detect early stages of PAH and understand its progression. The study includes patients with various forms of PAH and healthy individuals for comparison.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1

71 Participants Needed

Personalized Pain Management for Spinal Fusion

Pittsburgh, Pennsylvania
The purpose of this collaborative CTSA application is to develop an innovative perioperative precision analgesia platform (PPAP) to improve analgesia and reduce serious immediate and long-term adverse outcomes of perioperative opioids in children undergoing painful surgery.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:10 - 21

300 Participants Needed

Treprostinil Palmitil for Pulmonary Arterial Hypertension

Indianapolis, Indiana
This trial is testing an inhalable medicine called TPIP to see if it can help people with high blood pressure in their lungs by making it easier for blood to flow through their lung arteries.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

102 Participants Needed

Treprostinil Palmitil for PAH

Chicago, Illinois
The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP in participants with PAH.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3

91 Participants Needed

Implantable Intravascular Catheter for Pulmonary Arterial Hypertension

Chicago, Illinois
The purpose of the DelIVery for PAH clinical study is to evaluate the safety of the Medtronic Model 10642 Implantable Intravascular Catheter when used with the Medtronic SynchroMed® II Implantable Infusion System to deliver Remodulin® (treprostinil) Injection. As of June 2021, PMA approval of the Implantable System for Remodulin (ISR) is no longer being pursued and development and commercialization efforts have been halted. The approximately 30 subjects still implanted with the PIVoT system require a pathway for continued support. This protocol is amended and is designed to allow such ongoing support.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

64 Participants Needed

Spironolactone for Pulmonary Arterial Hypertension

Bethesda, Maryland
Background: - High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. In spite of recent advances in treatment, the death rate remains unacceptably high. Lung blood vessel function can be harmed by progressive injuries, such as inflammation, leading to worsening of the disease. A drug called spironolactone has been known to improve blood vessel function and reduce inflammation. Some people with PAH take spironolactone to help treat fluid retention. However, its effect on inflammation and blood vessel function in patients with PAH is not known. Researchers want to see if spironolactone can help these conditions in people with PAH. Objectives: - To test the effectiveness of spironolactone in treating pulmonary arterial hypertension. Eligibility: - Individuals at least 18 years of age with pulmonary arterial hypertension. Design: * This study will last for 24 weeks. Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. * Participants will take either spironolactone or a placebo. They will take their study drug or placebo for 7 weeks. Treatment will be monitored with regular blood tests. * In Week 8, participants who have had no reaction to the treatment will receive a higher dose of the drug or placebo. * In Week 12, participants will have a study visit with heart and lung function tests. They will also have a 6-minute walk test, and provide blood and urine samples. * After additional study visits for blood samples, participants will have a final visit in Week 24. The tests from Week 12 will be repeated at this visit.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

70 Participants Needed

Intravenous ZMA001 for Pulmonary Arterial Hypertension

Bethesda, Maryland
Background: A number of diseases can cause a type of lung injury called pulmonary arterial hypertension (PAH). Most people who develop PAH do not survive more than a few years. A new study drug (ZMA001) may help. ZMA001 is a monoclonal antibody. This type of drug consists of proteins, made in a facility, that are very similar to proteins in a human body. But before giving ZMA001 to people sick with PAH, researchers want to find out how the drug affects healthy people. Objective: To test a drug (ZMA001) in healthy volunteers. Eligibility: Healthy adults aged 18 to 60 years. Design: Participants will be screened. They will have a physical exam with blood tests. They will have a urine test for drug use. They will have a test of their heart function. Participants will come to the clinic for 1 inpatient visit of up to 48 hours. ZMA001 is a liquid administered through a tube attached to a needle inserted into a vein in the arm. Participants will receive this drug only once, during their inpatient stay. Some participants will receive the drug; others will receive a placebo in Cohort 1 only. A placebo is a treatment that looks just like the real drug but contains no medicine. Participants will not know which treatment they are getting in Cohort 1. Cohorts 2-4 will receive a single dose of the study drug, administered through a tube attached to a needle inserted into a vein in the arm. After a screening visit, participants will have 1 inpatient visit and up to 8 outpatient visits over 16 weeks after receiving the treatment. Blood draws and other tests will be repeated. Each outpatient visit is approximately 2 hours long. This study is the first time ZMA001 will be administered to people.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 60

96 Participants Needed

MRI-Guided Catheterization for Heart Disease

Bethesda, Maryland
Background: A heart catheterization is a diagnostic heart procedure used to measure pressures and take pictures of the blood flow through the heart chambers. Magnetic resonance imaging (MRI) fluoroscopy shows continuous pictures of the heart chambers that doctors can watch while they work. Researchers want to test this procedure with catheterization tools routinely used in x-ray catheterization called guidewires. Guidewires will help move the heart catheter through the different heart chambers. Guidewires are usually considered unsafe during MRI because MRI can cause a guidewire to heat while inside the blood vessels and heart. Researchers are testing special low energy MRI settings that allow certain guidewires to be used during MRI catheterization without heating. Using these guidewires during MRI may help to decrease the amount of time you are in the MRI scanner, and the overall time the MRI catheterization procedure takes. Objectives: To test if certain MRI settings make it safe to use a guidewire during MRI fluoroscopy. Eligibility: Adults 18 and older whose doctors have recommended right heart catheterization. Design: Researchers will screen participants by reviewing their lab results and questionnaire answers. Participants may give 4 blood samples. Participants will be sedated. They will have a tube (catheter) placed in the groin, arm, or neck if they don t already have one. Patches on the skin will monitor heart rhythm. Special antennas, covered in pads, will be placed against the body. Participants will lie flat on a table that slides in and out of the MRI scanner as it makes pictures. Participants will get earplugs for the loud knocking noise. They can talk on an intercom. They will be inside the scanner for up to 2 hours. They can ask to stop at any time. During a heart catheterization, catheters will be inserted through the tubes already in place. The catheters are guided by MRI fluoroscopy into the chambers of the heart and vessels. The guidewire will help position the catheter.
No Placebo Group

Trial Details

Trial Status:Recruiting

100 Participants Needed

12

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Pulmonary Arterial Hypertension clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Pulmonary Arterial Hypertension clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Pulmonary Arterial Hypertension trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Pulmonary Arterial Hypertension is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Pulmonary Arterial Hypertension medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Pulmonary Arterial Hypertension clinical trials?

Most recently, we added 129Xe Imaging for Pulmonary Arterial Hypertension, Empagliflozin for Pulmonary Arterial Hypertension and Mobile Health Intervention for Pediatric PAH to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

Top Pulmonary Hypertension Clinical Trials

59 Hypertension Trials near Olathe, KS

47 Hypertension Trials near Houston, TX

39 Hypertension Trials near Akron, OH

40 Hypertension Trials near Overland Park, KS

36 Hypertension Trials near Columbus, OH

Top Pulmonary Embolism Clinical Trials

Top Pulmonary Fibrosis Clinical Trials

Top Idiopathic Pulmonary Fibrosis Clinical Trials

Top Chronic Obstructive Pulmonary Disease Clinical Trials

Top Idiopathic Intracranial Hypertension Clinical Trials

Top Dystonia Clinical Trials

By Trial

Selexipag for Pulmonary Arterial Hypertension

GB002 for Pulmonary Arterial Hypertension

PET Imaging for Pulmonary Arterial Hypertension

Sotatercept for Pulmonary Arterial Hypertension

Denervation System for Heart Failure and Pulmonary Hypertension

Aria CV System for Pulmonary Arterial Hypertension

High-Dose Macitentan for PAH

Noninvasive Ultrasound Technique for Portal Hypertension

Noninvasive SHAPE for Portal Hypertension

Oral Sildenafil for COPD

Hemodynamic Monitoring for Cardiogenic Shock

Left Atrial Appendage Exclusion for Stroke Prevention

Related Searches

Top Clinical Trials near Pittsburgh, PA

Top Neurofibromatosis-type-1 Clinical Trials

Neuromodulation for Schizophrenia

RO7790121 for Crohn's Disease

Deuterated Oxytocin for Postpartum Hemorrhage

Gene Therapy for Cystic Fibrosis

Montelukast for Gulf War Syndrome

Pozelimab + Cemdisiran for Macular Degeneration

Fenebrutinib for Multiple Sclerosis

MAP for Coaches Training for Sports Injury Prevention

N-acetylcysteine for Retinitis Pigmentosa

DB-1303 for Solid Cancers

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial